Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01968720 · ClinicalTrials.gov registry record · Phase 2
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
A Phase 2 study of Dyslipidemias and Hypertriglyceridemia, sponsored by Catabasis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 4
- Study locations
NCT01968720: Completed Phase 2 study of Dyslipidemias and Hypertriglyceridemia, sponsored by Catabasis Pharmaceuticals.
NCT01968720 is a Phase 2 study of Dyslipidemias and Hypertriglyceridemia that has completed, run by Catabasis Pharmaceuticals. The registered enrollment target is 16 participants, below the 232-participant average among 28 other Dyslipidemias trials with a reported enrollment target (93% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01968720, a Phase 2 study of Dyslipidemias and Hypertriglyceridemia, has completed, sponsored by Catabasis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to determine the safety and efficacy of multiple doses of CAT-2003 in patients with severe hypertriglyceridemia either naive or refractory to current therapy. The study will evaluate effects of CAT-2003 on fasting and postprandial total triglycerides and chylomicron triglyceride levels in patients with severe hypertriglyceridemia. This is a single-blind study. All patients will receive placebo for a 14 day treatment period and CAT-2003 for a 28 day treatment period.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CAT-2003
Study Locations (4)
Florida
- - Miami
Indiana
- - Indianapolis
Maine
- - Auburn
Ohio
- - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2013-10 |
| Est. Completion | 2014-04 |
| Phase | Phase 2 |
What the finished NCT01968720 record still lists
NCT01968720 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 232-participant average among 28 other Dyslipidemias trials with a reported enrollment target (93% lower).
The record links to 5 conditions, with Dyslipidemias appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01968720 reports a single indexed study location in Florida, Indiana, Maine.
Frequently Asked Questions
What is clinical trial NCT01968720 about?
NCT01968720 is a clinical study titled "Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia". The purpose of this study is to determine the safety and efficacy of multiple doses of CAT-2003 in patients with severe hypertriglyceridemia either naive or refractory to current therapy. The study will evaluate effects of CAT-2003 on fasting and postprandial total triglycerides and chylomicron trig...
What is the current status of trial NCT01968720?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2013-10. Estimated completion is 2014-04.
What conditions does trial NCT01968720 study?
This clinical trial studies the following conditions: Dyslipidemias, Hypertriglyceridemia, Hyperlipidemias, Metabolic Diseases, Lipid Metabolism Disorders.
What interventions are being tested in trial NCT01968720?
The interventions under investigation include: Placebo (DRUG), CAT-2003 (DRUG).
Who is sponsoring clinical trial NCT01968720?
This trial is sponsored by Catabasis Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01968720 being conducted?
This trial has 4 study locations across Florida, Indiana, Maine, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dyslipidemias
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01968720's enrollment target sits among peer trials
16 28th of 28 the lowest of 28 other Dyslipidemias trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dyslipidemias trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Causal Mechanisms in Adolescent Arterial Stiffness
ACTIVE NOT RECRUITING · Phase 2
-
Study of ARO-APOC3 in Adults With Dyslipidemia
COMPLETED · Phase 2
-
Dose Response Effects of Pecan Consumption
RECRUITING · NA
-
Cottonseed Oil Dose Response
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia